Discussion of the literature and supporting references for many of the recommendations summarized in the present guideline can be found in greater detail in the upcoming ACCF/AHA guideline for manage- ment of patients undergoing PCI,174 ACCF/AHA guideline for management of patients with peripheral artery dis- ease,175,176 the AHA effectiveness-based guidelines for car- diovascular disease prevention in women,46 and in the AHA/ American Stroke Association guidelines for the prevention of stroke in patients with stroke or transient ischemic attack.123 Finally, the practitioner should exercise judgment in initi- ating the various recommendations if the patient has recently experienced an acute event. Disclosures Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Sidney C. Smith, Jr University of North Carolina None None None None None None None Emelia J. Benjamin Boston University School of Medicine None None None None None None None Robert O. Bonow Northwestern University None None None None None None None Lynne T. Braun Rush University Medical Center NIH-Coinvestigator, Reducing Health Disparity in African American Women: Adherence to Physical Activity* None None None None None None Mark A. Creager Brigham and Women s Hospital Merck ; Sanofi Aventis None None None None Pfizer*; Sanofi Aventis*; Merck (via TIMI group)*; AstraZeneca* None Barry A. Franklin William Beaumont Hospital None None I receive honoraria throughout the year for talks to hospitals (ie, medical grand rounds) and cardiac rehabilitation state associations* None None Smart Balance Scientific Advisory Board* None Raymond J. Gibbons Mayo Clinic King Pharmaceuticals ; TherOx ; VeloMedix None None None None Cardiovascular Clinical Studies*; Medscape (heart.org)*; Molecular Insight Pharmaceuticals*; TherOx*; Lantheus Medical Imaging* None Scott M. Grundy UT Southwestern Medical Center Sankyo Perot Foundation None None None AstraZeneca*; Merck*; Merck/Schering- Plough*; Pfizer* (Relationships ended 3 years ago) None Loren F. Hiratzka Cardiovascular and Thoracic Surgeons/ Tri-Health Inc None None None None None None None Daniel W. Jones University of Mississippi None None None None None None None Donald M. Lloyd-Jones Northwestern None None None None None None None Margo Minissian Cedars Sinai Medical Center RWise Study, Co-Investigator, Gilead Sciences None None None None None None Lori Mosca Columbia University NIH* None None None None Advise & Consent, Inc.*; Gilead Science*; Rowpar Pharmaceuticals, Inc. ; Sanofi-Aventis* None Eric D. Peterson Duke University Medical Center Bristol-Myers Squibb/Sanofi ; Eli Lilly ; Merck/Schering-Plough ; Johnson & Johnson None None None None None None Ralph L. Sacco University of Miami NINDS Northern Manhattan Study* None None None None Boehringer Ingelheim* (ended March 2009); GlaxoSmithKline (ended March 2009)*; Sanofi Aventis* (ended March 2009); DSMB (Atrial Fibrillation Trial institutionally sponsored by Population Health Research Institute at McMaster University, Hamilton, Ontario)* None (Continued) Smith et al AHA/ACCF Secondary Prevention: 2011 Update 2465 Writing Group Disclosures, Continued Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other John Spertus Mid America Heart Institute Amgen ; Bristol-Myers Squibb/Sanofi ; Eli Lilly ; Cordis ; NIH ; ACCF ; AHA Atherotech ; Roche Diagnostics None None Holds copyright to Kansas City Cardiomyopathy Questionnaire ; holds copyright to Peripheral Artery Questionnaire*; holds copyright to Seattle Angina Questionnaire St. Jude Medical*; United HealthCare*; Amgen* None James H. Stein University of Wisconsin School of Medicine and Public Health Sanofi-Aventis (ended July 2009); Siemens Medical Solutions (ended July 2009); SonoSite (ended None Abbott* and Takeda* (no permanent remuneration; all money to charity. 